Loading
Life sciences · Journal article
Experimental and Clinical Endocrinology & Diabetes · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Insulin resistance is a central pathological feature underlying various metabolic disorders, involving complex mechanisms and multi-organ dysfunction. This study investigates the role of the acute-phase protein orosomucoid in systemic glucose homeostasis. This study utilized high-fat diet–induced obese mice to model insulin resistance. The genetic deletion of orosomucoid 1 was applied, and the metabolic effects of exogenous orosomucoid administration were examined. Molecular analysis included assessing protein kinase B phosphorylation. The dependency of observed benefits on specific receptors was tested using pharmacological inhibition of C–C chemokine receptor type 5 and evaluation of the leptin receptor’s role. We demonstrate that genetic deletion of orosomucoid 1 induces insulin resistance, whereas exogenous orosomucoid administration improves glucose tolerance and insulin sensitivity in high-fat diet mice. At the molecular level, orosomucoid augments insulin-induced protein kinase B phosphorylation. Notably, these metabolic benefits are independent of the leptin receptor but are critically dependent on the C–C chemokine receptor type 5, as demonstrated by pharmacological inhibition. Our findings establish orosomucoid as an endogenous insulin sensitizer via the C–C chemokine receptor type 5/protein kinase B pathway, coordinately ameliorating insulin resistance across multiple metabolic organs and highlighting its therapeutic potential as a novel target for metabolic disorders.